The adverse events of toripalimab in nasopharyngeal carcinoma based on FAERS database and bibliometric analysis.

PLoS One · 2025 · PMC12180722 · PMID 40540517

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a notable trendno p-value reported

There was a notable trend observed in adverse events related to toripalimab, particularly regarding immune-mediated hepatic disorders (n = 7, ROR 343.20, PRR 340.56, IC 8.40, EBGM 338.64) and immune-mediated myocarditis (n = 3, ROR 214.68, PRR 213.97, IC 7.74, EBGM 213.22).

also in 2,105 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.